Last checked at 15 Apr 2021 07:00
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Full Year Results
Gaithersburg, Maryland - 15 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, will be announcing its financial results for the year ended 31 December 2020 on Tuesday, 20 April 2021.
Doug Doerfler, Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will host a conference call for analysts at 14.00pm BST the day of the announcement. The presentation will be available on the Investors section of MaxCyte's website on the day of the meeting at https://investors.maxcyte.com/news-events/documents-presentations .
###
For further information please contact:
MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer | +1 301 944 1660 |
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden
|
+44 (0)20 7886 2500 |
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith
|
+44 (0)20 7260 1000 |
Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams | +44 (0) 20 7710 7600 |
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott / Chris Welsh |
+44 (0)203 709 5700 maxcyte@consilium-comms.com |
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies that are driving the next‐generation of cell-based therapies and making a meaningful difference for patients. The Company's technology is employed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte has granted 12 strategic platform licences to leading cell-based therapy developers. Through 2020, MaxCyte has granted licenses for more than 140 cell therapy programs, with over 100 licensed for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, U.S. For more information, visit www.maxcyte.com.